Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Initiation
ProQR Therapeutics assumed with an Overweight at Cantor Fitzgerald » 07:53
05/12/22
05/12
07:53
05/12/22
07:53
PRQR

ProQR Therapeutics

/

+

Cantor Fitzgerald analyst…

Cantor Fitzgerald analyst Jennifer Kim assumed coverage of ProQR Therapeutics with an Overweight rating with an unchanged price target of $3.50. The analyst believes the company's select ophthalmology programs and potential product pipeline and partnership opportunities from its Axiomer RNA base-editing technology platform is underappreciated at current share levels. The potential market opportunity for ultevursen for USH2A-mediated Usher syndrome and retinitis pigmentosa is underappreciated, Kim tells investors in a research note.

ShowHide Related Items >><<
PRQR ProQR Therapeutics
/

+

PRQR ProQR Therapeutics
/

+

05/09/22 H.C. Wainwright
ProQR Therapeutics price target lowered to $2 from $4 at H.C. Wainwright
04/19/22 Cantor Fitzgerald
ProQR Therapeutics price target lowered to $3.50 from $6.00 at Cantor Fitzgerald
04/14/22 Chardan
ProQR Therapeutics price target lowered to $2.50 from $8 at Chardan
03/15/22 Citi
ProQR Therapeutics price target lowered to $1 from $1.70 at Citi
PRQR ProQR Therapeutics
/

+

PRQR ProQR Therapeutics
/

+

Recommendations
ProQR Therapeutics price target lowered to $2 from $4 at H.C. Wainwright » 06:12
05/09/22
05/09
06:12
05/09/22
06:12
PRQR

ProQR Therapeutics

/

+

H.C. Wainwright analyst…

H.C. Wainwright analyst Andrew Fein lowered the firm's price target on ProQR Therapeutics to $2 from $4 and keeps a Buy rating on the shares.

ShowHide Related Items >><<
PRQR ProQR Therapeutics
/

+

PRQR ProQR Therapeutics
/

+

04/19/22 Cantor Fitzgerald
ProQR Therapeutics price target lowered to $3.50 from $6.00 at Cantor Fitzgerald
04/14/22 Chardan
ProQR Therapeutics price target lowered to $2.50 from $8 at Chardan
03/15/22 Citi
ProQR Therapeutics price target lowered to $1 from $1.70 at Citi
02/14/22 Citi
ProQR Therapeutics downgraded to Neutral from Buy at Citi
PRQR ProQR Therapeutics
/

+

PRQR ProQR Therapeutics
/

+

Earnings
ProQR Therapeutics reports Q1 EPS (20c), consensus (25c) » 16:59
05/05/22
05/05
16:59
05/05/22
16:59
PRQR

ProQR Therapeutics

/

+

The company said it has…

The company said it has cash runway into 2025.

ShowHide Related Items >><<
PRQR ProQR Therapeutics
/

+

PRQR ProQR Therapeutics
/

+

04/19/22 Cantor Fitzgerald
ProQR Therapeutics price target lowered to $3.50 from $6.00 at Cantor Fitzgerald
04/14/22 Chardan
ProQR Therapeutics price target lowered to $2.50 from $8 at Chardan
03/15/22 Citi
ProQR Therapeutics price target lowered to $1 from $1.70 at Citi
02/14/22 Citi
ProQR Therapeutics downgraded to Neutral from Buy at Citi
PRQR ProQR Therapeutics
/

+

PRQR ProQR Therapeutics
/

+

Conference/Events
Association for Research in Vision & Ophthalmology to hold annual meeting » 04:55
05/04/22
05/04
04:55
05/04/22
04:55
ABBV

AbbVie

$149.61 /

+1.74 (+1.18%)

, ABEO

Abeona Therapeutics

/

+

, ADVM

Adverum Biotechnologies

$1.15 /

+0.03 (+2.69%)

, AERI

Aerie Pharmaceuticals

$7.96 /

+0.47 (+6.28%)

, AGN

Bought by ABBV

$193.08 /

+ (+0.00%)

, AGTC

Applied Genetic

/

+

, BAYRY

Bayer

$16.04 /

+0.23 (+1.45%)

, BMRN

BioMarin

$83.49 /

+0.18 (+0.22%)

, CE

Celanese

$150.37 /

+4.53 (+3.11%)

, CELU

Celularity

$11.38 /

-0.28 (-2.40%)

, DNA

Ginkgo Bioworks

$3.23 /

+0.105 (+3.36%)

, EDIT

Editas Medicine

$14.18 /

-0.1 (-0.70%)

, HZNP

Horizon Therapeutics

$94.70 /

-3.375 (-3.44%)

, JNJ

Johnson & Johnson

$178.28 /

-0.37 (-0.21%)

, KALA

Kala Pharmaceuticals

/

+

, KOD

Kodiak Sciences

$6.39 /

-0.065 (-1.01%)

, LCTX

Lineage Cell Therapeutics

$1.27 /

+0.065 (+5.39%)

, PRQR

ProQR Therapeutics

/

+

, REGN

Regeneron

$660.09 /

+7.73 (+1.18%)

, RGNX

Regenxbio

$28.25 /

-0.15 (-0.53%)

, RHHBY

Roche

$45.13 /

-0.37 (-0.81%)

, STOK

Stoke Therapeutics

$14.77 /

-0.21 (-1.40%)

, UBX

Unity Biotechnology

/

+

ARVO 2022 to be held in…

ARVO 2022 to be held in Denver, CO on May 1-4.

ShowHide Related Items >><<
UBX Unity Biotechnology
/

+

STOK Stoke Therapeutics
$14.77 /

-0.21 (-1.40%)

RHHBY Roche
$45.13 /

-0.37 (-0.81%)

RGNX Regenxbio
$28.25 /

-0.15 (-0.53%)

REGN Regeneron
$660.09 /

+7.73 (+1.18%)

PRQR ProQR Therapeutics
/

+

LCTX Lineage Cell Therapeutics
$1.27 /

+0.065 (+5.39%)

KOD Kodiak Sciences
$6.39 /

-0.065 (-1.01%)

KALA Kala Pharmaceuticals
/

+

JNJ Johnson & Johnson
$178.28 /

-0.37 (-0.21%)

HZNP Horizon Therapeutics
$94.70 /

-3.375 (-3.44%)

EDIT Editas Medicine
$14.18 /

-0.1 (-0.70%)

DNA Ginkgo Bioworks
$3.23 /

+0.105 (+3.36%)

CELU Celularity
$11.38 /

-0.28 (-2.40%)

CE Celanese
$150.37 /

+4.53 (+3.11%)

BMRN BioMarin
$83.49 /

+0.18 (+0.22%)

BAYRY Bayer
$16.04 /

+0.23 (+1.45%)

AGTC Applied Genetic
/

+

AERI Aerie Pharmaceuticals
$7.96 /

+0.47 (+6.28%)

ADVM Adverum Biotechnologies
$1.15 /

+0.03 (+2.69%)

ABEO Abeona Therapeutics
/

+

ABBV AbbVie
$149.61 /

+1.74 (+1.18%)

ABBV AbbVie
$149.61 /

+1.74 (+1.18%)

05/03/22 Morgan Stanley
Vertex upgraded to Equal Weight at Morgan Stanley following AbbVie failure
05/02/22 Morgan Stanley
AbbVie's recent weakness a buying opportunity, says Morgan Stanley
05/02/22 Wells Fargo
AbbVie price target raised to $200 from $165 at Wells Fargo
05/02/22 Cowen
Genmab initiated with a Market Perform at Cowen
ABEO Abeona Therapeutics
/

+

11/30/21 SVB Leerink
Abeona Therapeutics downgraded to Market Perform from Outperform at SVB Leerink
11/29/21 H.C. Wainwright
Abeona Therapeutics price target lowered to $4 from $5 at H.C. Wainwright
07/19/21 H.C. Wainwright
Abeona Therapeutics price target lowered to $5 from $8 at H.C. Wainwright
ADVM Adverum Biotechnologies
$1.15 /

+0.03 (+2.69%)

03/29/22 Chardan
Adverum Biotechnologies transferred with Neutral at Chardan
07/23/21
Fly Intel: Top five analyst downgrades
07/23/21 Goldman Sachs
Adverum Biotechnologies downgraded to Neutral from Buy at Goldman Sachs
07/23/21 SVB Leerink
Adverum Biotechnologies price target lowered to $2 from $5
AERI Aerie Pharmaceuticals
$7.96 /

+0.47 (+6.28%)

02/28/22 Citi
Aerie Pharmaceuticals price target lowered to $13 from $23 at Citi
02/25/22 Cowen
Aerie Pharmaceuticals price target lowered to $25 from $30 at Cowen
AGN Bought by ABBV
$193.08 /

+ (+0.00%)

AGTC Applied Genetic
/

+

03/29/22 Chardan
Applied Genetic transferred with Buy rating at Chardan
02/14/22 Stifel
Stifel keeps Buy rating on Applied Genetic, lowers price target to $10
09/24/21 Roth Capital
Applied Genetic near-term readouts 'major catalysts,' says Roth Capital
07/09/21 Chardan
Applied Genetic coverage transferred at Chardan
BAYRY Bayer
$16.04 /

+0.23 (+1.45%)

04/25/22 Morgan Stanley
Bayer price target raised to EUR 83 from EUR 77 at Morgan Stanley
04/05/22 Barclays
Bayer upgraded to Overweight from Equal Weight at Barclays
03/15/22 Barclays
Bayer price target raised to EUR 60 from EUR 55 at Barclays
03/14/22 Jefferies
Bayer initiated with a Buy at Jefferies
BMRN BioMarin
$83.49 /

+0.18 (+0.22%)

04/28/22 Wedbush
BioMarin price target lowered to $147 from $155 at Wedbush
04/25/22 Morgan Stanley
BioMarin upgraded to Overweight from Equal Weight at Morgan Stanley
02/24/22 Piper Sandler
BioMarin price target raised to $125 from $121 at Piper Sandler
01/10/22 JPMorgan
JPMorgan bullish on BioMarin following CEO 'encouraging' presentation
CE Celanese
$150.37 /

+4.53 (+3.11%)

04/13/22 Fermium Research
DuPont price target lowered to $78 from $87 at Fermium Research
04/08/22 JPMorgan
Celanese added to Analyst Focus List at JPMorgan
02/22/22 Deutsche Bank
Celanese likely to split-up in 2024 or 2025, says Deutsche Bank
02/22/22 Piper Sandler
Celanese downgraded to Underweight from Neutral at Piper Sandler
CELU Celularity
$11.38 /

-0.28 (-2.40%)

04/06/22 Truist
Celularity downgraded to Hold from Buy at Truist
04/01/22 Oppenheimer
Celularity price target raised to $10 from $9 at Oppenheimer
01/27/22 Oppenheimer
Celularity initiated with an Outperform at Oppenheimer
11/24/21 Morgan Stanley
Celularity initiated with an Equal Weight at Morgan Stanley
DNA Ginkgo Bioworks
$3.23 /

+0.105 (+3.36%)

03/31/22 BTIG
Ginkgo Bioworks price target lowered to $6 from $12 at BTIG
03/29/22 Cowen
Ginkgo Bioworks weakness a buying opportunity, says Cowen
03/02/22 Cowen
Ginkgo Bioworks initiated with an Outperform at Cowen
02/23/22 Goldman Sachs
Ginkgo Bioworks initiated with a Neutral at Goldman Sachs
EDIT Editas Medicine
$14.18 /

-0.1 (-0.70%)

04/18/22 Baird
Editas Medicine price target lowered to $33 from $44 at Baird
02/25/22 SVB Leerink
Editas Medicine price target lowered to $27 from $41 at SVB Leerink
02/25/22 Barclays
Editas Medicine price target lowered to $18 from $39 at Barclays
02/25/22 Chardan
Editas Medicine price target lowered to $60 from $75 at Chardan
HZNP Horizon Therapeutics
$94.70 /

-3.375 (-3.44%)

03/14/22 Oppenheimer
Horizon Therapeutics initiated with an Outperform at Oppenheimer
01/26/22 Piper Sandler
Horizon Therapeutics price target lowered to $133 from $143 at Piper Sandler
01/18/22 JPMorgan
Horizon Therapeutics valuation 'compelling' after selloff, says JPMorgan
12/08/21
Fly Intel: Top five analyst initiations
JNJ Johnson & Johnson
$178.28 /

-0.37 (-0.21%)

04/29/22 Chardan
Emergent BioSolutions price target lowered to $65 from $75 at Chardan
04/20/22 Credit Suisse
Johnson & Johnson price target raised to $205 from $200 at Credit Suisse
04/20/22 Citi
Johnson & Johnson price target raised to $210 from $203 at Citi
04/19/22 Stifel
J&J notes more-positive Q1 trends, U.S. Spine 'a relative outlier,' says Stifel
KALA Kala Pharmaceuticals
/

+

03/30/22 Northland
Kala Pharmaceuticals price target lowered to $4 from $6 at Northland
03/30/22 H.C. Wainwright
Kala Pharmaceuticals price target lowered to $6 from $9 at H.C. Wainwright
03/30/22 JPMorgan
Kala Pharmaceuticals downgraded to Underweight from Neutral at JPMorgan
12/15/21 Wedbush
Kala Pharmaceuticals assumed with an Outperform, $6 target at Wedbush
KOD Kodiak Sciences
$6.39 /

-0.065 (-1.01%)

04/13/22 Truist
Kodiak Sciences price target lowered to $10 from $35 at Truist
03/29/22 Chardan
Kodiak Sciences price target lowered to $19 from $82.50 at Chardan
02/28/22 Roth Capital
Kodiak Sciences price target lowered to $75 from $149 at Roth Capital
02/24/22 Truist
Kodiak Sciences price target lowered to $35 from $147 at Truist
LCTX Lineage Cell Therapeutics
$1.27 /

+0.065 (+5.39%)

04/25/22 H.C. Wainwright
Lineage Cell's PNC program 'an expected and logical move,' says H.C. Wainwright
08/19/21 Noble Capital
Lineage Cell Therapeutics initiated with an Outperform at Noble Capital
PRQR ProQR Therapeutics
/

+

04/19/22 Cantor Fitzgerald
ProQR Therapeutics price target lowered to $3.50 from $6.00 at Cantor Fitzgerald
04/14/22 Chardan
ProQR Therapeutics price target lowered to $2.50 from $8 at Chardan
03/15/22 Citi
ProQR Therapeutics price target lowered to $1 from $1.70 at Citi
02/14/22 Citi
ProQR Therapeutics downgraded to Neutral from Buy at Citi
REGN Regeneron
$660.09 /

+7.73 (+1.18%)

04/20/22 Cowen
Regeneron price target raised to $645 from $640 at Cowen
04/20/22 BTIG
Checkmate Pharmaceuticals downgraded to Neutral from Buy at BTIG
04/19/22 Baird
Decibel could be next target for Regeneron, says Baird
04/12/22 Barclays
Regeneron price target raised to $745 from $700 at Barclays
RGNX Regenxbio
$28.25 /

-0.15 (-0.53%)

03/29/22 Chardan
Regenxbio price target lowered to $76 from $90 at Chardan
02/10/22 SVB Leerink
Regenxbio price target lowered to $29 from $35 at SVB Leerink
12/15/21
Fly Intel: Top five analyst initiations
12/15/21 Wedbush
Wedbush initiates Regenxbio with a Neutral rating, price target of $29
RHHBY Roche
$45.13 /

-0.37 (-0.81%)

05/03/22 Piper Sandler
Piper keeps Overweight rating on Ionis after Biogen's Spinraza beat
04/26/22 Stifel
Arvinas price target lowered to $85 from $93 at Stifel
04/19/22 UBS
Roche downgraded to Sell from Neutral at UBS
STOK Stoke Therapeutics
$14.77 /

-0.21 (-1.40%)

01/31/22 Jefferies
Stoke Therapeutics initiated with a Buy at Jefferies
12/03/21
Fly Intel: Top five analyst initiations
12/03/21 BofA
Stoke Therapeutics initiated with a Buy at BofA
12/03/21 BofA
Stoke Therapeutics initiated with a Buy at BofA
UBX Unity Biotechnology
/

+

01/04/22 Roth Capital
Unity Biotechnology upgraded to Buy at Roth Capital on 2022 clinical plans
01/04/22 Roth Capital
Unity Biotechnology upgraded to Buy from Neutral at Roth Capital
12/15/21 Wedbush
Wedbush bullish on Unity Biotechnology, initiates with an Outperform
12/15/21 Wedbush
Unity Biotechnology assumed with an Outperform at Wedbush
UBX Unity Biotechnology
/

+

STOK Stoke Therapeutics
$14.77 /

-0.21 (-1.40%)

RHHBY Roche
$45.13 /

-0.37 (-0.81%)

RGNX Regenxbio
$28.25 /

-0.15 (-0.53%)

REGN Regeneron
$660.09 /

+7.73 (+1.18%)

PRQR ProQR Therapeutics
/

+

LCTX Lineage Cell Therapeutics
$1.27 /

+0.065 (+5.39%)

KOD Kodiak Sciences
$6.39 /

-0.065 (-1.01%)

KALA Kala Pharmaceuticals
/

+

JNJ Johnson & Johnson
$178.28 /

-0.37 (-0.21%)

HZNP Horizon Therapeutics
$94.70 /

-3.375 (-3.44%)

EDIT Editas Medicine
$14.18 /

-0.1 (-0.70%)

DNA Ginkgo Bioworks
$3.23 /

+0.105 (+3.36%)

CELU Celularity
$11.38 /

-0.28 (-2.40%)

CE Celanese
$150.37 /

+4.53 (+3.11%)

BMRN BioMarin
$83.49 /

+0.18 (+0.22%)

BAYRY Bayer
$16.04 /

+0.23 (+1.45%)

AGTC Applied Genetic
/

+

AERI Aerie Pharmaceuticals
$7.96 /

+0.47 (+6.28%)

ADVM Adverum Biotechnologies
$1.15 /

+0.03 (+2.69%)

ABEO Abeona Therapeutics
/

+

ABBV AbbVie
$149.61 /

+1.74 (+1.18%)

  • 22
    Mar
  • 17
    Dec
RHHBY Roche
$45.13 /

-0.37 (-0.81%)

REGN Regeneron
$660.09 /

+7.73 (+1.18%)

LCTX Lineage Cell Therapeutics
$1.27 /

+0.065 (+5.39%)

JNJ Johnson & Johnson
$178.28 /

-0.37 (-0.21%)

HZNP Horizon Therapeutics
$94.70 /

-3.375 (-3.44%)

CE Celanese
$150.37 /

+4.53 (+3.11%)

BAYRY Bayer
$16.04 /

+0.23 (+1.45%)

ABBV AbbVie
$149.61 /

+1.74 (+1.18%)

STOK Stoke Therapeutics
$14.77 /

-0.21 (-1.40%)

RHHBY Roche
$45.13 /

-0.37 (-0.81%)

RGNX Regenxbio
$28.25 /

-0.15 (-0.53%)

REGN Regeneron
$660.09 /

+7.73 (+1.18%)

PRQR ProQR Therapeutics
/

+

KOD Kodiak Sciences
$6.39 /

-0.065 (-1.01%)

JNJ Johnson & Johnson
$178.28 /

-0.37 (-0.21%)

HZNP Horizon Therapeutics
$94.70 /

-3.375 (-3.44%)

EDIT Editas Medicine
$14.18 /

-0.1 (-0.70%)

DNA Ginkgo Bioworks
$3.23 /

+0.105 (+3.36%)

CELU Celularity
$11.38 /

-0.28 (-2.40%)

CE Celanese
$150.37 /

+4.53 (+3.11%)

BMRN BioMarin
$83.49 /

+0.18 (+0.22%)

AGTC Applied Genetic
/

+

AERI Aerie Pharmaceuticals
$7.96 /

+0.47 (+6.28%)

ABBV AbbVie
$149.61 /

+1.74 (+1.18%)

KALA Kala Pharmaceuticals
/

+

JNJ Johnson & Johnson
$178.28 /

-0.37 (-0.21%)

DNA Ginkgo Bioworks
$3.23 /

+0.105 (+3.36%)

CELU Celularity
$11.38 /

-0.28 (-2.40%)

CE Celanese
$150.37 /

+4.53 (+3.11%)

ABBV AbbVie
$149.61 /

+1.74 (+1.18%)

Conference/Events
Association for Research in Vision & Ophthalmology to hold annual meeting » 04:55
05/03/22
05/03
04:55
05/03/22
04:55
ABBV

AbbVie

$147.87 /

+1.03 (+0.70%)

, ABEO

Abeona Therapeutics

/

+

, ADVM

Adverum Biotechnologies

$1.11 /

+0.045 (+4.23%)

, AERI

Aerie Pharmaceuticals

$7.50 /

+0.385 (+5.41%)

, AGN

Bought by ABBV

$193.08 /

+ (+0.00%)

, AGTC

Applied Genetic

/

+

, BAYRY

Bayer

$15.81 /

-0.575 (-3.51%)

, BMRN

BioMarin

$83.30 /

+1.935 (+2.38%)

, CE

Celanese

$145.86 /

-1.025 (-0.70%)

, CELU

Celularity

$11.65 /

-0.055 (-0.47%)

, DNA

Ginkgo Bioworks

$3.13 /

+0.23 (+7.94%)

, EDIT

Editas Medicine

$14.28 /

+1.03 (+7.77%)

, HZNP

Horizon Therapeutics

$98.08 /

-0.445 (-0.45%)

, JNJ

Johnson & Johnson

$178.65 /

-1.98 (-1.10%)

, KALA

Kala Pharmaceuticals

/

+

, KOD

Kodiak Sciences

$6.45 /

+0.425 (+7.06%)

, LCTX

Lineage Cell Therapeutics

$1.21 /

-0.01 (-0.82%)

, PRQR

ProQR Therapeutics

/

+

, REGN

Regeneron

$652.21 /

-6.68 (-1.01%)

, RGNX

Regenxbio

$28.42 /

+0.67 (+2.41%)

, RHHBY

Roche

$45.50 /

-0.68 (-1.47%)

, STOK

Stoke Therapeutics

$14.98 /

+0.58 (+4.03%)

, UBX

Unity Biotechnology

/

+

ARVO 2022 to be held in…

ARVO 2022 to be held in Denver, CO on May 1-4.

ShowHide Related Items >><<
UBX Unity Biotechnology
/

+

STOK Stoke Therapeutics
$14.98 /

+0.58 (+4.03%)

RHHBY Roche
$45.50 /

-0.68 (-1.47%)

RGNX Regenxbio
$28.42 /

+0.67 (+2.41%)

REGN Regeneron
$652.21 /

-6.68 (-1.01%)

PRQR ProQR Therapeutics
/

+

LCTX Lineage Cell Therapeutics
$1.21 /

-0.01 (-0.82%)

KOD Kodiak Sciences
$6.45 /

+0.425 (+7.06%)

KALA Kala Pharmaceuticals
/

+

JNJ Johnson & Johnson
$178.65 /

-1.98 (-1.10%)

HZNP Horizon Therapeutics
$98.08 /

-0.445 (-0.45%)

EDIT Editas Medicine
$14.28 /

+1.03 (+7.77%)

DNA Ginkgo Bioworks
$3.13 /

+0.23 (+7.94%)

CELU Celularity
$11.65 /

-0.055 (-0.47%)

CE Celanese
$145.86 /

-1.025 (-0.70%)

BMRN BioMarin
$83.30 /

+1.935 (+2.38%)

BAYRY Bayer
$15.81 /

-0.575 (-3.51%)

AGTC Applied Genetic
/

+

AERI Aerie Pharmaceuticals
$7.50 /

+0.385 (+5.41%)

ADVM Adverum Biotechnologies
$1.11 /

+0.045 (+4.23%)

ABEO Abeona Therapeutics
/

+

ABBV AbbVie
$147.87 /

+1.03 (+0.70%)

ABBV AbbVie
$147.87 /

+1.03 (+0.70%)

05/02/22 Morgan Stanley
AbbVie's recent weakness a buying opportunity, says Morgan Stanley
05/02/22 Wells Fargo
AbbVie price target raised to $200 from $165 at Wells Fargo
05/02/22 Cowen
Genmab initiated with a Market Perform at Cowen
05/02/22 JPMorgan
AbbVie selloff Friday 'very much overdone,' says JPMorgan
ABEO Abeona Therapeutics
/

+

11/30/21 SVB Leerink
Abeona Therapeutics downgraded to Market Perform from Outperform at SVB Leerink
11/29/21 H.C. Wainwright
Abeona Therapeutics price target lowered to $4 from $5 at H.C. Wainwright
07/19/21 H.C. Wainwright
Abeona Therapeutics price target lowered to $5 from $8 at H.C. Wainwright
ADVM Adverum Biotechnologies
$1.11 /

+0.045 (+4.23%)

03/29/22 Chardan
Adverum Biotechnologies transferred with Neutral at Chardan
07/23/21
Fly Intel: Top five analyst downgrades
07/23/21 Goldman Sachs
Adverum Biotechnologies downgraded to Neutral from Buy at Goldman Sachs
07/23/21 SVB Leerink
Adverum Biotechnologies price target lowered to $2 from $5
AERI Aerie Pharmaceuticals
$7.50 /

+0.385 (+5.41%)

02/28/22 Citi
Aerie Pharmaceuticals price target lowered to $13 from $23 at Citi
02/25/22 Cowen
Aerie Pharmaceuticals price target lowered to $25 from $30 at Cowen
AGN Bought by ABBV
$193.08 /

+ (+0.00%)

AGTC Applied Genetic
/

+

03/29/22 Chardan
Applied Genetic transferred with Buy rating at Chardan
02/14/22 Stifel
Stifel keeps Buy rating on Applied Genetic, lowers price target to $10
09/24/21 Roth Capital
Applied Genetic near-term readouts 'major catalysts,' says Roth Capital
07/09/21 Chardan
Applied Genetic coverage transferred at Chardan
BAYRY Bayer
$15.81 /

-0.575 (-3.51%)

04/25/22 Morgan Stanley
Bayer price target raised to EUR 83 from EUR 77 at Morgan Stanley
04/05/22 Barclays
Bayer upgraded to Overweight from Equal Weight at Barclays
03/15/22 Barclays
Bayer price target raised to EUR 60 from EUR 55 at Barclays
03/14/22 Jefferies
Bayer initiated with a Buy at Jefferies
BMRN BioMarin
$83.30 /

+1.935 (+2.38%)

04/28/22 Wedbush
BioMarin price target lowered to $147 from $155 at Wedbush
04/25/22 Morgan Stanley
BioMarin upgraded to Overweight from Equal Weight at Morgan Stanley
02/24/22 Piper Sandler
BioMarin price target raised to $125 from $121 at Piper Sandler
01/10/22 JPMorgan
JPMorgan bullish on BioMarin following CEO 'encouraging' presentation
CE Celanese
$145.86 /

-1.025 (-0.70%)

04/13/22 Fermium Research
DuPont price target lowered to $78 from $87 at Fermium Research
04/08/22 JPMorgan
Celanese added to Analyst Focus List at JPMorgan
02/22/22 Deutsche Bank
Celanese likely to split-up in 2024 or 2025, says Deutsche Bank
02/22/22 Piper Sandler
Celanese downgraded to Underweight from Neutral at Piper Sandler
CELU Celularity
$11.65 /

-0.055 (-0.47%)

04/06/22 Truist
Celularity downgraded to Hold from Buy at Truist
04/01/22 Oppenheimer
Celularity price target raised to $10 from $9 at Oppenheimer
01/27/22 Oppenheimer
Celularity initiated with an Outperform at Oppenheimer
11/24/21 Morgan Stanley
Celularity initiated with an Equal Weight at Morgan Stanley
DNA Ginkgo Bioworks
$3.13 /

+0.23 (+7.94%)

03/31/22 BTIG
Ginkgo Bioworks price target lowered to $6 from $12 at BTIG
03/29/22 Cowen
Ginkgo Bioworks weakness a buying opportunity, says Cowen
03/02/22 Cowen
Ginkgo Bioworks initiated with an Outperform at Cowen
02/23/22 Goldman Sachs
Ginkgo Bioworks initiated with a Neutral at Goldman Sachs
EDIT Editas Medicine
$14.28 /

+1.03 (+7.77%)

04/18/22 Baird
Editas Medicine price target lowered to $33 from $44 at Baird
02/25/22 SVB Leerink
Editas Medicine price target lowered to $27 from $41 at SVB Leerink
02/25/22 Barclays
Editas Medicine price target lowered to $18 from $39 at Barclays
02/25/22 Chardan
Editas Medicine price target lowered to $60 from $75 at Chardan
HZNP Horizon Therapeutics
$98.08 /

-0.445 (-0.45%)

03/14/22 Oppenheimer
Horizon Therapeutics initiated with an Outperform at Oppenheimer
01/26/22 Piper Sandler
Horizon Therapeutics price target lowered to $133 from $143 at Piper Sandler
01/18/22 JPMorgan
Horizon Therapeutics valuation 'compelling' after selloff, says JPMorgan
12/08/21
Fly Intel: Top five analyst initiations
JNJ Johnson & Johnson
$178.65 /

-1.98 (-1.10%)

04/29/22 Chardan
Emergent BioSolutions price target lowered to $65 from $75 at Chardan
04/20/22 Credit Suisse
Johnson & Johnson price target raised to $205 from $200 at Credit Suisse
04/20/22 Citi
Johnson & Johnson price target raised to $210 from $203 at Citi
04/19/22 Stifel
J&J notes more-positive Q1 trends, U.S. Spine 'a relative outlier,' says Stifel
KALA Kala Pharmaceuticals
/

+

03/30/22 Northland
Kala Pharmaceuticals price target lowered to $4 from $6 at Northland
03/30/22 H.C. Wainwright
Kala Pharmaceuticals price target lowered to $6 from $9 at H.C. Wainwright
03/30/22 JPMorgan
Kala Pharmaceuticals downgraded to Underweight from Neutral at JPMorgan
12/15/21 Wedbush
Kala Pharmaceuticals assumed with an Outperform, $6 target at Wedbush
KOD Kodiak Sciences
$6.45 /

+0.425 (+7.06%)

04/13/22 Truist
Kodiak Sciences price target lowered to $10 from $35 at Truist
03/29/22 Chardan
Kodiak Sciences price target lowered to $19 from $82.50 at Chardan
02/28/22 Roth Capital
Kodiak Sciences price target lowered to $75 from $149 at Roth Capital
02/24/22 Truist
Kodiak Sciences price target lowered to $35 from $147 at Truist
LCTX Lineage Cell Therapeutics
$1.21 /

-0.01 (-0.82%)

04/25/22 H.C. Wainwright
Lineage Cell's PNC program 'an expected and logical move,' says H.C. Wainwright
08/19/21 Noble Capital
Lineage Cell Therapeutics initiated with an Outperform at Noble Capital
PRQR ProQR Therapeutics
/

+

04/19/22 Cantor Fitzgerald
ProQR Therapeutics price target lowered to $3.50 from $6.00 at Cantor Fitzgerald
04/14/22 Chardan
ProQR Therapeutics price target lowered to $2.50 from $8 at Chardan
03/15/22 Citi
ProQR Therapeutics price target lowered to $1 from $1.70 at Citi
02/14/22 Citi
ProQR Therapeutics downgraded to Neutral from Buy at Citi
REGN Regeneron
$652.21 /

-6.68 (-1.01%)

04/20/22 Cowen
Regeneron price target raised to $645 from $640 at Cowen
04/20/22 BTIG
Checkmate Pharmaceuticals downgraded to Neutral from Buy at BTIG
04/19/22 Baird
Decibel could be next target for Regeneron, says Baird
04/12/22 Barclays
Regeneron price target raised to $745 from $700 at Barclays
RGNX Regenxbio
$28.42 /

+0.67 (+2.41%)

03/29/22 Chardan
Regenxbio price target lowered to $76 from $90 at Chardan
02/10/22 SVB Leerink
Regenxbio price target lowered to $29 from $35 at SVB Leerink
12/15/21
Fly Intel: Top five analyst initiations
12/15/21 Wedbush
Wedbush initiates Regenxbio with a Neutral rating, price target of $29
RHHBY Roche
$45.50 /

-0.68 (-1.47%)

04/26/22 Stifel
Arvinas price target lowered to $85 from $93 at Stifel
04/19/22 UBS
Roche downgraded to Sell from Neutral at UBS
04/14/22 Barclays
Roche price target raised to CHF 450 from CHF 415 at Barclays
STOK Stoke Therapeutics
$14.98 /

+0.58 (+4.03%)

01/31/22 Jefferies
Stoke Therapeutics initiated with a Buy at Jefferies
12/03/21
Fly Intel: Top five analyst initiations
12/03/21 BofA
Stoke Therapeutics initiated with a Buy at BofA
12/03/21 BofA
Stoke Therapeutics initiated with a Buy at BofA
UBX Unity Biotechnology
/

+

01/04/22 Roth Capital
Unity Biotechnology upgraded to Buy at Roth Capital on 2022 clinical plans
01/04/22 Roth Capital
Unity Biotechnology upgraded to Buy from Neutral at Roth Capital
12/15/21 Wedbush
Wedbush bullish on Unity Biotechnology, initiates with an Outperform
12/15/21 Wedbush
Unity Biotechnology assumed with an Outperform at Wedbush
UBX Unity Biotechnology
/

+

STOK Stoke Therapeutics
$14.98 /

+0.58 (+4.03%)

RHHBY Roche
$45.50 /

-0.68 (-1.47%)

RGNX Regenxbio
$28.42 /

+0.67 (+2.41%)

REGN Regeneron
$652.21 /

-6.68 (-1.01%)

PRQR ProQR Therapeutics
/

+

LCTX Lineage Cell Therapeutics
$1.21 /

-0.01 (-0.82%)

KOD Kodiak Sciences
$6.45 /

+0.425 (+7.06%)

KALA Kala Pharmaceuticals
/

+

JNJ Johnson & Johnson
$178.65 /

-1.98 (-1.10%)

HZNP Horizon Therapeutics
$98.08 /

-0.445 (-0.45%)

EDIT Editas Medicine
$14.28 /

+1.03 (+7.77%)

DNA Ginkgo Bioworks
$3.13 /

+0.23 (+7.94%)

CELU Celularity
$11.65 /

-0.055 (-0.47%)

CE Celanese
$145.86 /

-1.025 (-0.70%)

BMRN BioMarin
$83.30 /

+1.935 (+2.38%)

BAYRY Bayer
$15.81 /

-0.575 (-3.51%)

AGTC Applied Genetic
/

+

AERI Aerie Pharmaceuticals
$7.50 /

+0.385 (+5.41%)

ADVM Adverum Biotechnologies
$1.11 /

+0.045 (+4.23%)

ABEO Abeona Therapeutics
/

+

ABBV AbbVie
$147.87 /

+1.03 (+0.70%)

  • 22
    Mar
  • 17
    Dec
RHHBY Roche
$45.50 /

-0.68 (-1.47%)

REGN Regeneron
$652.21 /

-6.68 (-1.01%)

LCTX Lineage Cell Therapeutics
$1.21 /

-0.01 (-0.82%)

JNJ Johnson & Johnson
$178.65 /

-1.98 (-1.10%)

HZNP Horizon Therapeutics
$98.08 /

-0.445 (-0.45%)

CE Celanese
$145.86 /

-1.025 (-0.70%)

BAYRY Bayer
$15.81 /

-0.575 (-3.51%)

ABBV AbbVie
$147.87 /

+1.03 (+0.70%)

STOK Stoke Therapeutics
$14.98 /

+0.58 (+4.03%)

RHHBY Roche
$45.50 /

-0.68 (-1.47%)

RGNX Regenxbio
$28.42 /

+0.67 (+2.41%)

REGN Regeneron
$652.21 /

-6.68 (-1.01%)

PRQR ProQR Therapeutics
/

+

KOD Kodiak Sciences
$6.45 /

+0.425 (+7.06%)

JNJ Johnson & Johnson
$178.65 /

-1.98 (-1.10%)

HZNP Horizon Therapeutics
$98.08 /

-0.445 (-0.45%)

EDIT Editas Medicine
$14.28 /

+1.03 (+7.77%)

DNA Ginkgo Bioworks
$3.13 /

+0.23 (+7.94%)

CELU Celularity
$11.65 /

-0.055 (-0.47%)

CE Celanese
$145.86 /

-1.025 (-0.70%)

BMRN BioMarin
$83.30 /

+1.935 (+2.38%)

AGTC Applied Genetic
/

+

AERI Aerie Pharmaceuticals
$7.50 /

+0.385 (+5.41%)

ABBV AbbVie
$147.87 /

+1.03 (+0.70%)

KALA Kala Pharmaceuticals
/

+

JNJ Johnson & Johnson
$178.65 /

-1.98 (-1.10%)

DNA Ginkgo Bioworks
$3.13 /

+0.23 (+7.94%)

CELU Celularity
$11.65 /

-0.055 (-0.47%)

CE Celanese
$145.86 /

-1.025 (-0.70%)

ABBV AbbVie
$147.87 /

+1.03 (+0.70%)

Conference/Events
Association for Research in Vision & Ophthalmology to hold annual meeting » 09:48
05/02/22
05/02
09:48
05/02/22
09:48
ABBV

AbbVie

$146.26 /

-0.58 (-0.39%)

, ABEO

Abeona Therapeutics

/

+

, ADVM

Adverum Biotechnologies

$1.12 /

+0.05 (+4.69%)

, AERI

Aerie Pharmaceuticals

$7.08 /

-0.03 (-0.42%)

, AGN

Bought by ABBV

$193.08 /

+ (+0.00%)

, AGTC

Applied Genetic

/

+

, BAYRY

Bayer

$16.39 /

+0.015 (+0.09%)

, BMRN

BioMarin

$81.76 /

+0.4 (+0.49%)

, CE

Celanese

$148.01 /

+1.13 (+0.77%)

, CELU

Celularity

$11.59 /

-0.115 (-0.98%)

, DNA

Ginkgo Bioworks

$2.81 /

-0.085 (-2.94%)

, EDIT

Editas Medicine

$13.28 /

+0.03 (+0.23%)

, HZNP

Horizon Therapeutics

$97.60 /

-0.92 (-0.93%)

, JNJ

Johnson & Johnson

$180.45 /

-0.185 (-0.10%)

, KALA

Kala Pharmaceuticals

/

+

, KOD

Kodiak Sciences

$6.03 /

+0.01 (+0.17%)

, LCTX

Lineage Cell Therapeutics

$1.18 /

-0.035 (-2.88%)

, PRQR

ProQR Therapeutics

/

+

, REGN

Regeneron

$658.67 /

-0.225 (-0.03%)

, RGNX

Regenxbio

$27.61 /

-0.14 (-0.50%)

, RHHBY

Roche

$46.18 /

-0.4 (-0.86%)

, STOK

Stoke Therapeutics

$14.40 /

+ (+0.00%)

, UBX

Unity Biotechnology

/

+

ARVO 2022 to be held in…

ARVO 2022 to be held in Denver, CO on May 1-4.

ShowHide Related Items >><<
UBX Unity Biotechnology
/

+

STOK Stoke Therapeutics
$14.40 /

+ (+0.00%)

RHHBY Roche
$46.18 /

-0.4 (-0.86%)

RGNX Regenxbio
$27.61 /

-0.14 (-0.50%)

REGN Regeneron
$658.67 /

-0.225 (-0.03%)

PRQR ProQR Therapeutics
/

+

LCTX Lineage Cell Therapeutics
$1.18 /

-0.035 (-2.88%)

KOD Kodiak Sciences
$6.03 /

+0.01 (+0.17%)

KALA Kala Pharmaceuticals
/

+

JNJ Johnson & Johnson
$180.45 /

-0.185 (-0.10%)

HZNP Horizon Therapeutics
$97.60 /

-0.92 (-0.93%)

EDIT Editas Medicine
$13.28 /

+0.03 (+0.23%)

DNA Ginkgo Bioworks
$2.81 /

-0.085 (-2.94%)

CELU Celularity
$11.59 /

-0.115 (-0.98%)

CE Celanese
$148.01 /

+1.13 (+0.77%)

BMRN BioMarin
$81.76 /

+0.4 (+0.49%)

BAYRY Bayer
$16.39 /

+0.015 (+0.09%)

AGTC Applied Genetic
/

+

AERI Aerie Pharmaceuticals
$7.08 /

-0.03 (-0.42%)

ADVM Adverum Biotechnologies
$1.12 /

+0.05 (+4.69%)

ABEO Abeona Therapeutics
/

+

ABBV AbbVie
$146.26 /

-0.58 (-0.39%)

ABBV AbbVie
$146.26 /

-0.58 (-0.39%)

05/02/22 Morgan Stanley
AbbVie's recent weakness a buying opportunity, says Morgan Stanley
05/02/22 Wells Fargo
AbbVie price target raised to $200 from $165 at Wells Fargo
05/02/22 Cowen
Genmab initiated with a Market Perform at Cowen
05/02/22 JPMorgan
AbbVie selloff Friday 'very much overdone,' says JPMorgan
ABEO Abeona Therapeutics
/

+

11/30/21 SVB Leerink
Abeona Therapeutics downgraded to Market Perform from Outperform at SVB Leerink
11/29/21 H.C. Wainwright
Abeona Therapeutics price target lowered to $4 from $5 at H.C. Wainwright
07/19/21 H.C. Wainwright
Abeona Therapeutics price target lowered to $5 from $8 at H.C. Wainwright
ADVM Adverum Biotechnologies
$1.12 /

+0.05 (+4.69%)

03/29/22 Chardan
Adverum Biotechnologies transferred with Neutral at Chardan
07/23/21
Fly Intel: Top five analyst downgrades
07/23/21 Goldman Sachs
Adverum Biotechnologies downgraded to Neutral from Buy at Goldman Sachs
07/23/21 SVB Leerink
Adverum Biotechnologies price target lowered to $2 from $5
AERI Aerie Pharmaceuticals
$7.08 /

-0.03 (-0.42%)

02/28/22 Citi
Aerie Pharmaceuticals price target lowered to $13 from $23 at Citi
02/25/22 Cowen
Aerie Pharmaceuticals price target lowered to $25 from $30 at Cowen
AGN Bought by ABBV
$193.08 /

+ (+0.00%)

AGTC Applied Genetic
/

+

03/29/22 Chardan
Applied Genetic transferred with Buy rating at Chardan
02/14/22 Stifel
Stifel keeps Buy rating on Applied Genetic, lowers price target to $10
09/24/21 Roth Capital
Applied Genetic near-term readouts 'major catalysts,' says Roth Capital
07/09/21 Chardan
Applied Genetic coverage transferred at Chardan
BAYRY Bayer
$16.39 /

+0.015 (+0.09%)

04/25/22 Morgan Stanley
Bayer price target raised to EUR 83 from EUR 77 at Morgan Stanley
04/05/22 Barclays
Bayer upgraded to Overweight from Equal Weight at Barclays
03/15/22 Barclays
Bayer price target raised to EUR 60 from EUR 55 at Barclays
03/14/22 Jefferies
Bayer initiated with a Buy at Jefferies
BMRN BioMarin
$81.76 /

+0.4 (+0.49%)

04/28/22 Wedbush
BioMarin price target lowered to $147 from $155 at Wedbush
04/25/22 Morgan Stanley
BioMarin upgraded to Overweight from Equal Weight at Morgan Stanley
02/24/22 Piper Sandler
BioMarin price target raised to $125 from $121 at Piper Sandler
01/10/22 JPMorgan
JPMorgan bullish on BioMarin following CEO 'encouraging' presentation
CE Celanese
$148.01 /

+1.13 (+0.77%)

04/13/22 Fermium Research
DuPont price target lowered to $78 from $87 at Fermium Research
04/08/22 JPMorgan
Celanese added to Analyst Focus List at JPMorgan
02/22/22 Deutsche Bank
Celanese likely to split-up in 2024 or 2025, says Deutsche Bank
02/22/22 Piper Sandler
Celanese downgraded to Underweight from Neutral at Piper Sandler
CELU Celularity
$11.59 /

-0.115 (-0.98%)

04/06/22 Truist
Celularity downgraded to Hold from Buy at Truist
04/01/22 Oppenheimer
Celularity price target raised to $10 from $9 at Oppenheimer
01/27/22 Oppenheimer
Celularity initiated with an Outperform at Oppenheimer
11/24/21 Morgan Stanley
Celularity initiated with an Equal Weight at Morgan Stanley
DNA Ginkgo Bioworks
$2.81 /

-0.085 (-2.94%)

03/31/22 BTIG
Ginkgo Bioworks price target lowered to $6 from $12 at BTIG
03/29/22 Cowen
Ginkgo Bioworks weakness a buying opportunity, says Cowen
03/02/22 Cowen
Ginkgo Bioworks initiated with an Outperform at Cowen
02/23/22 Goldman Sachs
Ginkgo Bioworks initiated with a Neutral at Goldman Sachs
EDIT Editas Medicine
$13.28 /

+0.03 (+0.23%)

04/18/22 Baird
Editas Medicine price target lowered to $33 from $44 at Baird
02/25/22 SVB Leerink
Editas Medicine price target lowered to $27 from $41 at SVB Leerink
02/25/22 Barclays
Editas Medicine price target lowered to $18 from $39 at Barclays
02/25/22 Chardan
Editas Medicine price target lowered to $60 from $75 at Chardan
HZNP Horizon Therapeutics
$97.60 /

-0.92 (-0.93%)

03/14/22 Oppenheimer
Horizon Therapeutics initiated with an Outperform at Oppenheimer
01/26/22 Piper Sandler
Horizon Therapeutics price target lowered to $133 from $143 at Piper Sandler
01/18/22 JPMorgan
Horizon Therapeutics valuation 'compelling' after selloff, says JPMorgan
12/08/21
Fly Intel: Top five analyst initiations
JNJ Johnson & Johnson
$180.45 /

-0.185 (-0.10%)

04/29/22 Chardan
Emergent BioSolutions price target lowered to $65 from $75 at Chardan
04/20/22 Credit Suisse
Johnson & Johnson price target raised to $205 from $200 at Credit Suisse
04/20/22 Citi
Johnson & Johnson price target raised to $210 from $203 at Citi
04/19/22 Stifel
J&J notes more-positive Q1 trends, U.S. Spine 'a relative outlier,' says Stifel
KALA Kala Pharmaceuticals
/

+

03/30/22 Northland
Kala Pharmaceuticals price target lowered to $4 from $6 at Northland
03/30/22 H.C. Wainwright
Kala Pharmaceuticals price target lowered to $6 from $9 at H.C. Wainwright
03/30/22 JPMorgan
Kala Pharmaceuticals downgraded to Underweight from Neutral at JPMorgan
12/15/21 Wedbush
Kala Pharmaceuticals assumed with an Outperform, $6 target at Wedbush
KOD Kodiak Sciences
$6.03 /

+0.01 (+0.17%)

04/13/22 Truist
Kodiak Sciences price target lowered to $10 from $35 at Truist
03/29/22 Chardan
Kodiak Sciences price target lowered to $19 from $82.50 at Chardan
02/28/22 Roth Capital
Kodiak Sciences price target lowered to $75 from $149 at Roth Capital
02/24/22 Truist
Kodiak Sciences price target lowered to $35 from $147 at Truist
LCTX Lineage Cell Therapeutics
$1.18 /

-0.035 (-2.88%)

04/25/22 H.C. Wainwright
Lineage Cell's PNC program 'an expected and logical move,' says H.C. Wainwright
08/19/21 Noble Capital
Lineage Cell Therapeutics initiated with an Outperform at Noble Capital
PRQR ProQR Therapeutics
/

+

04/19/22 Cantor Fitzgerald
ProQR Therapeutics price target lowered to $3.50 from $6.00 at Cantor Fitzgerald
04/14/22 Chardan
ProQR Therapeutics price target lowered to $2.50 from $8 at Chardan
03/15/22 Citi
ProQR Therapeutics price target lowered to $1 from $1.70 at Citi
02/14/22 Citi
ProQR Therapeutics downgraded to Neutral from Buy at Citi
REGN Regeneron
$658.67 /

-0.225 (-0.03%)

04/20/22 Cowen
Regeneron price target raised to $645 from $640 at Cowen
04/20/22 BTIG
Checkmate Pharmaceuticals downgraded to Neutral from Buy at BTIG
04/19/22 Baird
Decibel could be next target for Regeneron, says Baird
04/12/22 Barclays
Regeneron price target raised to $745 from $700 at Barclays
RGNX Regenxbio
$27.61 /

-0.14 (-0.50%)

03/29/22 Chardan
Regenxbio price target lowered to $76 from $90 at Chardan
02/10/22 SVB Leerink
Regenxbio price target lowered to $29 from $35 at SVB Leerink
12/15/21
Fly Intel: Top five analyst initiations
12/15/21 Wedbush
Wedbush initiates Regenxbio with a Neutral rating, price target of $29
RHHBY Roche
$46.18 /

-0.4 (-0.86%)

04/26/22 Stifel
Arvinas price target lowered to $85 from $93 at Stifel
04/19/22 UBS
Roche downgraded to Sell from Neutral at UBS
04/14/22 Barclays
Roche price target raised to CHF 450 from CHF 415 at Barclays
STOK Stoke Therapeutics
$14.40 /

+ (+0.00%)

01/31/22 Jefferies
Stoke Therapeutics initiated with a Buy at Jefferies
12/03/21
Fly Intel: Top five analyst initiations
12/03/21 BofA
Stoke Therapeutics initiated with a Buy at BofA
12/03/21 BofA
Stoke Therapeutics initiated with a Buy at BofA
UBX Unity Biotechnology
/

+

01/04/22 Roth Capital
Unity Biotechnology upgraded to Buy at Roth Capital on 2022 clinical plans
01/04/22 Roth Capital
Unity Biotechnology upgraded to Buy from Neutral at Roth Capital
12/15/21 Wedbush
Wedbush bullish on Unity Biotechnology, initiates with an Outperform
12/15/21 Wedbush
Unity Biotechnology assumed with an Outperform at Wedbush
UBX Unity Biotechnology
/

+

STOK Stoke Therapeutics
$14.40 /

+ (+0.00%)

RHHBY Roche
$46.18 /

-0.4 (-0.86%)

RGNX Regenxbio
$27.61 /

-0.14 (-0.50%)

REGN Regeneron
$658.67 /

-0.225 (-0.03%)

PRQR ProQR Therapeutics
/

+

LCTX Lineage Cell Therapeutics
$1.18 /

-0.035 (-2.88%)

KOD Kodiak Sciences
$6.03 /

+0.01 (+0.17%)

KALA Kala Pharmaceuticals
/

+

JNJ Johnson & Johnson
$180.45 /

-0.185 (-0.10%)

HZNP Horizon Therapeutics
$97.60 /

-0.92 (-0.93%)

EDIT Editas Medicine
$13.28 /

+0.03 (+0.23%)

DNA Ginkgo Bioworks
$2.81 /

-0.085 (-2.94%)

CELU Celularity
$11.59 /

-0.115 (-0.98%)

CE Celanese
$148.01 /

+1.13 (+0.77%)

BMRN BioMarin
$81.76 /

+0.4 (+0.49%)

BAYRY Bayer
$16.39 /

+0.015 (+0.09%)

AGTC Applied Genetic
/

+

AERI Aerie Pharmaceuticals
$7.08 /

-0.03 (-0.42%)

ADVM Adverum Biotechnologies
$1.12 /

+0.05 (+4.69%)

ABEO Abeona Therapeutics
/

+

ABBV AbbVie
$146.26 /

-0.58 (-0.39%)

  • 22
    Mar
  • 17
    Dec
RHHBY Roche
$46.18 /

-0.4 (-0.86%)

REGN Regeneron
$658.67 /

-0.225 (-0.03%)

LCTX Lineage Cell Therapeutics
$1.18 /

-0.035 (-2.88%)

JNJ Johnson & Johnson
$180.45 /

-0.185 (-0.10%)

HZNP Horizon Therapeutics
$97.60 /

-0.92 (-0.93%)

CE Celanese
$148.01 /

+1.13 (+0.77%)

BAYRY Bayer
$16.39 /

+0.015 (+0.09%)

ABBV AbbVie
$146.26 /

-0.58 (-0.39%)

STOK Stoke Therapeutics
$14.40 /

+ (+0.00%)

RHHBY Roche
$46.18 /

-0.4 (-0.86%)

RGNX Regenxbio
$27.61 /

-0.14 (-0.50%)

REGN Regeneron
$658.67 /

-0.225 (-0.03%)

PRQR ProQR Therapeutics
/

+

KOD Kodiak Sciences
$6.03 /

+0.01 (+0.17%)

JNJ Johnson & Johnson
$180.45 /

-0.185 (-0.10%)

HZNP Horizon Therapeutics
$97.60 /

-0.92 (-0.93%)

EDIT Editas Medicine
$13.28 /

+0.03 (+0.23%)

DNA Ginkgo Bioworks
$2.81 /

-0.085 (-2.94%)

CELU Celularity
$11.59 /

-0.115 (-0.98%)

CE Celanese
$148.01 /

+1.13 (+0.77%)

BMRN BioMarin
$81.76 /

+0.4 (+0.49%)

AGTC Applied Genetic
/

+

AERI Aerie Pharmaceuticals
$7.08 /

-0.03 (-0.42%)

ABBV AbbVie
$146.26 /

-0.58 (-0.39%)

KALA Kala Pharmaceuticals
/

+

JNJ Johnson & Johnson
$180.45 /

-0.185 (-0.10%)

DNA Ginkgo Bioworks
$2.81 /

-0.085 (-2.94%)

CELU Celularity
$11.59 /

-0.115 (-0.98%)

CE Celanese
$148.01 /

+1.13 (+0.77%)

ABBV AbbVie
$146.26 /

-0.58 (-0.39%)

Over a month ago
Recommendations
ProQR Therapeutics price target lowered to $3.50 from $6.00 at Cantor Fitzgerald » 08:00
04/19/22
04/19
08:00
04/19/22
08:00
PRQR

ProQR Therapeutics

/

+

Cantor Fitzgerald analyst…

Cantor Fitzgerald analyst Brian Cheng lowered the firm's price target on ProQR Therapeutics to $3.50 from $6.00 and keeps an Overweight rating on the shares. ProQR had earlier announced a number of operational updates, and is suspending its work in the early-stage QR-1123 and QR-504a programs in autosomal dominant retinitis pigmentosa and cutting its workforce by 30%, Cheng tells investors in a research note.

ShowHide Related Items >><<
PRQR ProQR Therapeutics
/

+

PRQR ProQR Therapeutics
/

+

04/14/22 Chardan
ProQR Therapeutics price target lowered to $2.50 from $8 at Chardan
03/15/22 Citi
ProQR Therapeutics price target lowered to $1 from $1.70 at Citi
02/14/22 Citi
ProQR Therapeutics downgraded to Neutral from Buy at Citi
02/14/22 Raymond James
ProQR Therapeutics downgraded to Market Perform from Strong Buy at Raymond James
PRQR ProQR Therapeutics
/

+

PRQR ProQR Therapeutics
/

+

Recommendations
ProQR Therapeutics price target lowered to $2.50 from $8 at Chardan » 07:23
04/14/22
04/14
07:23
04/14/22
07:23
PRQR

ProQR Therapeutics

/

+

Chardan analyst Keay…

Chardan analyst Keay Nakae lowered the firm's price target on ProQR Therapeutics to $2.50 from $8 and keeps a Buy rating on the shares after the company announced plans to restructure, including a 30% workforce reduction. The company intends to continue the phase II/III Illuminate trial, the pediatric phase II/III Brighten trial and the InSight phase Ib/II open-label extension study for sepofarsen as a treatment for CEP290-mediated Leber's congenital amaurosis 10 until further regulatory guidance, Nakae noted.

ShowHide Related Items >><<
PRQR ProQR Therapeutics
/

+

PRQR ProQR Therapeutics
/

+

03/15/22 Citi
ProQR Therapeutics price target lowered to $1 from $1.70 at Citi
02/14/22 Citi
ProQR Therapeutics downgraded to Neutral from Buy at Citi
02/14/22 Raymond James
ProQR Therapeutics downgraded to Market Perform from Strong Buy at Raymond James
02/14/22 JMP Securities
ProQR Therapeutics price target lowered to $8 from $29 at JMP Securities
PRQR ProQR Therapeutics
/

+

PRQR ProQR Therapeutics
/

+

Hot Stocks
ProQR Therapeutics announces additional sepofarsen Illuminate trial analyses » 07:16
04/13/22
04/13
07:16
04/13/22
07:16
PRQR

ProQR Therapeutics

/

+

Following the top-line…

Following the top-line announcement in February 2022 that Illuminate, ProQR's pivotal Phase 2/3 trial of sepofarsen in CEP290-mediated LCA10, did not meet the primary endpoint of Best Corrected Visual Acuity at Month 12 compared to a sham procedure control group, comprehensive post-hoc analyses of the trial were undertaken which revealed: No technical errors in the trial conduct, data handling, or the drug product used. The overall safety profile of sepofarsen was consistent with earlier trials. When the effect in the treatment eye was compared to the untreated contralateral eye in the same patient, at Month 12, a benefit in vision was observed as a mean change from baseline in BCVA of -0.12 logMAR in the sepofarsen treated groups. This effect was not observed in the sham treated group with the same comparison. Other endpoints showed similar effect when comparing treatment to contralateral eye, including Full Field Stimulus Testing. These findings were supported by the patient reported outcomes analyses, based on the Patient Global Impressions-Change that demonstrated that 61% of patients in the treatment groups reported an improvement in vision, as well as by Visual Function Questionnaire 25. Overall, the post-hoc analyses showed that the efficacy signal seen with sepofarsen when comparing active treatment and sham eyes to their corresponding contralateral eyes across BCVA, FST, and other endpoints, including PROs, was more consistent with the results seen in earlier findings, where the contralateral eye was used as the control. Based on these results, ProQR will focus on the following core activities related to sepofarsen: In Q3, the Company plans to meet with the EMA and FDA to discuss these data from the Illuminate trial. Following this discussion, ProQR will share an update in Q3 or early Q4, depending on timing of regulatory meetings. Based on the recommendation of the Data Safety and Monitoring Committee, the Company currently plans to continue Illuminate, which is a 2 year study, the Brighten pediatric study, and Insight, until further regulatory guidance, after which next steps will be determined. No further investments are planned at this time for new trials of sepofarsen or commercial preparations. Data from the Illuminate trial will be presented at the upcoming Seventh Annual Retinal Cell and Gene Therapy Innovation Summit, April 29, 2022, and the Association for Research in Vision and Ophthalmology Annual Meeting, May 1-4, 2022.

ShowHide Related Items >><<
PRQR ProQR Therapeutics
/

+

PRQR ProQR Therapeutics
/

+

03/15/22 Citi
ProQR Therapeutics price target lowered to $1 from $1.70 at Citi
02/14/22 Citi
ProQR Therapeutics downgraded to Neutral from Buy at Citi
02/14/22 Raymond James
ProQR Therapeutics downgraded to Market Perform from Strong Buy at Raymond James
02/14/22 JMP Securities
ProQR Therapeutics price target lowered to $8 from $29 at JMP Securities
PRQR ProQR Therapeutics
/

+

PRQR ProQR Therapeutics
/

+

Hot Stocks
ProQR Therapeutics expects cash to fund operations into 2025 » 07:13
04/13/22
04/13
07:13
04/13/22
07:13
PRQR

ProQR Therapeutics

/

+

The Company ended 2021…

The Company ended 2021 with EUR 187.5 million of cash and cash equivalents on its balance sheet and expects these resources, together with anticipated expense reductions resulting from a corporate restructuring and the strategic update announced today, will fund currently planned operations into 2025, and through several milestones, including the potential readout of the modified Phase 2/3 Sirius trial of ultevursen.

ShowHide Related Items >><<
PRQR ProQR Therapeutics
/

+

PRQR ProQR Therapeutics
/

+

03/15/22 Citi
ProQR Therapeutics price target lowered to $1 from $1.70 at Citi
02/14/22 Citi
ProQR Therapeutics downgraded to Neutral from Buy at Citi
02/14/22 Raymond James
ProQR Therapeutics downgraded to Market Perform from Strong Buy at Raymond James
02/14/22 JMP Securities
ProQR Therapeutics price target lowered to $8 from $29 at JMP Securities
PRQR ProQR Therapeutics
/

+

PRQR ProQR Therapeutics
/

+

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.